Part 2 of 5: Top 10 Oncogenic Markers in NSCLC for 2022: An interview with David Gandara MD

Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or undergoing late-stage evaluation that target genomic alterations and biomarkers, including EGFR, MET, HER3, NRG1, HER2, TROP2, ROS1, KRAS, NTRK, and RET.

This featured podcast includes interviews with some of the field’s top experts on where we are in terms of testing, safety and efficacy of therapies targeted to the top 10 oncogenic markers in 2022.